

# Agnes Y Y Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9906092/publications.pdf>

Version: 2024-02-01

81  
papers

8,668  
citations

147566

31  
h-index

74018

75  
g-index

82  
all docs

82  
docs citations

82  
times ranked

7121  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2003, 349, 146-153.   | 13.9 | 2,344     |
| 2  | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-520.   | 0.8  | 971       |
| 3  | Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 711-719.  | 13.9 | 614       |
| 4  | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 677.  | 3.8  | 530       |
| 5  | Venous Thromboembolism and Cancer: Risks and Outcomes. <i>Circulation</i> , 2003, 107, 171-21.  | 1.6  | 521       |
| 6  | American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. <i>Blood Advances</i> , 2021, 5, 927-974.  | 2.5  | 431       |
| 7  | Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019, 179, 1469.   | 2.6  | 283       |
| 8  | Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 1404-1408.  | 0.8  | 274       |
| 9  | Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. <i>BMJ, The</i> , 2021, 375, n2400. | 3.0  | 250       |
| 10 | Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. <i>Blood Reviews</i> , 2016, 30, 411-420.  | 2.8  | 236       |
| 11 | Guidance for the prevention and treatment of cancer-associated venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 81-91.   | 1.0  | 169       |
| 12 | Treatment of cancer-associated thrombosis. <i>Blood</i> , 2013, 122, 2310-2317.   | 0.6  | 158       |
| 13 | Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. <i>Blood Reviews</i> , 2021, 45, 100707.  | 2.8  | 137       |
| 14 | Perioperative Management of Dabigatran. <i>Circulation</i> , 2015, 132, 167-173.  | 1.6  | 133       |
| 15 | Cancer-associated venous thromboembolism. <i>Nature Reviews Disease Primers</i> , 2022, 8, 11.  | 18.1 | 130       |
| 16 | Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. <i>Blood</i> , 2015, 126, 597-603.   | 0.6  | 101       |
| 17 | Management of thrombosis in cancer: primary prevention and secondary prophylaxis. <i>British Journal of Haematology</i> , 2005, 128, 291-302.   | 1.2  | 97        |
| 18 | Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 1422-1430.   | 0.7  | 97        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Epidemiology and management of venous thromboembolism in patients with cancer. <i>Thrombosis Research</i> , 2003, 110, 167-172.  | 0.8 | 76        |
| 20 | Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. <i>Annals of Hematology</i> , 2015, 94, 329-336.              | 0.8 | 65        |
| 21 | Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1078-1085.                              | 0.8 | 60        |
| 22 | What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients'™ Quality of Life?. <i>Value in Health</i> , 2018, 21, 449-455.   | 0.1 | 58        |
| 23 | Thrombosis in Cancer: An Update on Prevention, Treatment, and Survival Benefits of Anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 144-149.                   | 0.9 | 52        |
| 24 | Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 664-669.          | 1.0 | 47        |
| 25 | A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 2020, 120, 702-713.                                 | 1.8 | 42        |
| 26 | Venous Thromboembolism in Older Adults: A Community-based Study. <i>American Journal of Medicine</i> , 2014, 127, 530-537.e3.  | 0.6 | 41        |
| 27 | Randomized trials of therapeutic heparin for COVID-19: A meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12638.  | 1.0 | 39        |
| 28 | Catheter-related thrombosis: lifeline or a pain in the neck?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 638-644.  | 0.9 | 38        |
| 29 | Thrombosis and Cancer: The Role of Screening for Occult Cancer and Recognizing the Underlying Biological Mechanisms. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 438-443. | 0.9 | 37        |
| 30 | Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism—Analysis of the CATCH Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 914-921.      | 1.8 | 37        |
| 31 | Anticoagulation practice patterns in COVID-19: A global survey. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 969-983.   | 1.0 | 35        |
| 32 | Treatment of established thrombotic events in patients with cancer. <i>Thrombosis Research</i> , 2012, 129, S146-S153.   | 0.8 | 32        |
| 33 | Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor cell cytokine release syndrome. <i>British Journal of Haematology</i> , 2020, 190, e150-e154.                 | 1.2 | 32        |
| 34 | Diagnosis and Treatment of Venous Thromboembolism. <i>Annual Review of Medicine</i> , 2002, 53, 15-33.   | 5.0 | 26        |
| 35 | Patient Experience of Living With Cancer-Associated Thrombosis in Canada (PELICANADA). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 154-160.  | 1.0 | 26        |
| 36 | Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. <i>Current Oncology</i> , 2021, 28, 5434-5451.   | 0.9 | 26        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Anticoagulant Therapy for Venous Thromboembolism in Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1650-1652.  | 13.9 | 25        |
| 38 | VTE in Patients with Cancer-Diagnosis, Prevention, and Treatment. <i>Thrombosis Research</i> , 2008, 123, S50-S54.  | 0.8  | 21        |
| 39 | When can we stop anticoagulation in patients with cancer-associated thrombosis?. <i>Blood</i> , 2017, 130, 2484-2490.   | 0.6  | 21        |
| 40 | The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer. <i>Thrombosis Research</i> , 2007, 120, S121-S127.   | 0.8  | 20        |
| 41 | COSIMO â€“ patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. <i>Thrombosis Journal</i> , 2018, 16, 21.  | 0.9  | 20        |
| 42 | Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism. <i>Thrombosis Research</i> , 2020, 188, 106-114.  | 0.8  | 19        |
| 43 | Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID) <i>Tj ETQq1 1 0,784314 rgBT /Over</i><br><i>Trials</i> , 2021, 22, 202. | 0.7  | 19        |
| 44 | Predictors of attempted inferior vena cava filters retrieval in a tertiary care centre. <i>Thrombosis Research</i> , 2014, 134, 300-304.  | 0.8  | 18        |
| 45 | Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 386-392.  | 1.0  | 18        |
| 46 | Treatment of Venous Thromboembolism in Cancer Patients. <i>Cancer Control</i> , 2005, 12, 17-21.  | 0.7  | 17        |
| 47 | Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants. <i>Thrombosis Research</i> , 2014, 133, S167-S171.   | 0.8  | 17        |
| 48 | When can we stop anticoagulation in patients with cancer-associated thrombosis?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 128-135.  | 0.9  | 15        |
| 49 | The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients. <i>Current Opinion in Pulmonary Medicine</i> , 2003, 9, 351-355.  | 1.2  | 14        |
| 50 | Overview of VTE treatment in cancer according to clinical guidelines. <i>Thrombosis Research</i> , 2018, 164, S162-S167.  | 0.8  | 14        |
| 51 | Treatment of venous thromboembolism in cancer patients: The dark side of the moon. <i>Cancer Treatment Reviews</i> , 2021, 96, 102190.  | 3.4  | 14        |
| 52 | Unanswered questions in cancer-associated thrombosis. <i>British Journal of Haematology</i> , 2022, 198, 812-825.   | 1.2  | 11        |
| 53 | Clinical practice guidelines on cancer-associated thrombosis: a review on scope and methodology. <i>Thrombosis Research</i> , 2016, 140, S119-S127.   | 0.8  | 10        |
| 54 | Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism â€“ The COSIMO study. <i>Thrombosis Research</i> , 2021, 206, 1-4.  | 0.8  | 10        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Treatment of venous thromboembolism in cancer patients. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 93-101.   | 0.7 | 9         |
| 56 | The roles of anticoagulants in patients with cancer. <i>Thrombosis Research</i> , 2010, 125, S8-S11.  | 0.8 | 9         |
| 57 | D-Dimer Levels as a Marker of Cutaneous Disease Activity. <i>JAMA Dermatology</i> , 2014, 150, 880.   | 2.0 | 9         |
| 58 | Update from the clinic: what's new in the diagnosis of cancer-associated thrombosis?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 167-174.                                 | 0.9 | 9         |
| 59 | Anti-thrombotic therapy in cancer patients. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 2213-2220.  | 0.9 | 8         |
| 60 | Management of incidental splanchnic vein thrombosis in cancer patients. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 318-320.   | 0.9 | 8         |
| 61 | Prevention and treatment of venous thromboembolism in patients with cancer. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 312-317.   | 0.9 | 7         |
| 62 | Thromboprophylaxis in Cancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 395-400.  | 1.5 | 7         |
| 63 | Novel or Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Cancer-Associated Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 237-243.                                      | 1.5 | 7         |
| 64 | Direct Oral Anticoagulants in Cancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 638-647.  | 1.5 | 7         |
| 65 | Antithrombotic Strategy in Cerebral Venous Thrombosis: Differences Between Neurologist and Hematologist Respondents in a Canadian Survey. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 116-119. | 0.3 | 6         |
| 66 | Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation. <i>JACC: CardioOncology</i> , 2021, 3, 425-427.   | 1.7 | 6         |
| 67 | How I treat and prevent venous thrombotic complications in patients with lymphoma. <i>Blood</i> , 2022, 139, 1489-1500.   | 0.6 | 5         |
| 68 | Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination. <i>Blood Advances</i> , 2022, 6, 3315-3320.   | 2.5 | 5         |
| 69 | Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol. <i>BMJ Open</i> , 2016, 6, e013263.                       | 0.8 | 4         |
| 70 | Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2020, 27, e32-e55.     | 1.9 | 4         |
| 71 | Thromboprophylaxis in Cancer Patients Undergoing Surgery. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 672-681.   | 1.5 | 3         |
| 72 | Venous thromboembolism and cancer: prevention and therapy. <i>Vnitřní Lekarství</i> , 2006, 52 Suppl 1, 127-8, 130-1.   | 0.1 | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 11, 100228. | 1.5 | 2         |
| 74 | Vaccine-induced prothrombotic immune thrombocytopenia without thrombosis may not require immune modulatory therapy: A case report. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .     | 1.0 | 2         |
| 75 | Prevention of Deep Vein Thrombosis in Cancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 699-706.   | 1.5 | 1         |
| 76 | Treatment of Venous Thrombosis. <i>Cancer Treatment and Research</i> , 2009, 148, 243-257.   | 0.2 | 0         |
| 77 | Tinzaparin vs Warfarin for Acute Venous Thromboembolism—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 200.   | 3.8 | 0         |
| 78 | The changing landscape of anticoagulation in cancer-associated thrombosis. <i>Blood Advances</i> , 2020, 4, 969-969.   | 2.5 | 0         |
| 79 | Annals for Hospitalists Inpatient Notes - Direct Oral Anticoagulants in Patients With Cancer—What Hospitalists Need to Know. <i>Annals of Internal Medicine</i> , 2021, 174, HO2-HO3.                          | 2.0 | 0         |
| 80 | Incidence and Outcomes of Catheter Related Thrombosis in Acute Leukemia: Single Centre Experience. <i>Blood</i> , 2016, 128, 3828-3828.  | 0.6 | 0         |
| 81 | The role of low-molecular-weight heparins in treating thrombosis. <i>The Journal of Supportive Oncology</i> , 2006, 4, 123-4.  | 2.3 | 0         |